ATS 2019 Virtual Final Program

DIVISION OF LUNG DISEASES, NHLBI/NIH L8 MOLECULAR IMAGING OF THE LUNG (PHASE 2) 12:15 p.m. - 1:15 p.m. KBHCCD Room D221/D225/D226 (Level 2) Target Audience Providers of lung health, fellows and other trainees, and basic researchers interested in lung biology and pulmonary imaging Objectives At the conclusion of this session, the participant will be able to: • learn new advances in molecular imaging of the lung; • understand how molecular imaging technology will improve early detection and monitoring of lung diseases; • understand the development and testing ofmolecular probes for pulmonary imaging. Molecular Imaging of the Lung (Phase 2) is an NHLBI-sponsored program that supports the development of novel imaging reagents and technologies that target pathways or cells involved in the pathobiology of pulmonary diseases. Speakers supported by this program will highlight recent advances in molecular imaging of the lungs, including the development, validation, and testing in human subjects of molecular probes targeting specific cell types and molecules involved in lung diseases. Chairing: T.S. Blackwell, MD, Nashville, TN S. Lin, PhD, Bethesda, MD 12:15 Folate Imaging to Assess Inflammation in COPD T.S. Blackwell, MD, Nashville, TN 12:25 Bugs, Drugs and the Local Milieu: New Tools for Precision Medicine S.K. Jain, MD, Baltimore, MD 12:35 Can CCR2 PET Phenotype Patients with Pulmonary Fibrosis? S.L. Brody, MD, ATSF, Saint Louis, MO 12:45 Collagen-Targeted Molecular Imaging: Initial Experience in IPF Patients S. Montesi, MD, Boston, MA 12:55 Molecular Imaging of Angiogenic Signaling in PAH P.B. Yu, MD, PhD, Boston, MA 1:05 In Vivo Imaging of Apoptosis and Disease Severity in COPD J.M. D’Armiento, MD, PhD, New York, NY MEET THE PROFESSOR SEMINARS CME Credits Available: 1 R Registration Fee: $70.00 (includes box lunch.) Attendance is limited. Pre-registration is required. 12:15 p.m. - 1:15 p.m. OMNI DALLAS DOWNTOWN MP401 THE INFLUENCE OF SEX HORMONES ON ALLERGIC DISEASE AND ASTHMA D.C. Newcomb, PhD, Nashville, TN Greenville Avenue (Level 2) MP402 BRONCHIECTASIS: CASE BASED CONTROVERSIES IN CLINICAL CARE A.E. O'Donnell, MD, Washington, DC G. Tino, MD, Philadelphia, PA Deep Ellum B (Level 2)) MP403 NEW FLEISCHNER SOCIETY GUIDELINES FOR PULMONARY NODULES A.C. Mehta, MBBS, ATSF, Cleveland, OH Deep Ellum A (Level 2) MP404 IMMUNE CHECKPOINT INHIBITOR PNEUMONITIS: CASES, QUESTIONS AND CONTROVERSIES P. Camus, MD, Dijon, France Arts District 1 (Level 2) MP405 STATISTICAL CHALLENGES IN THE ANALYSIS OF PULMONARY DATA: REAL WORLD EXAMPLES FROM THE DUKE CLINICAL RESEARCH INSTITUTE M. Neely, PhD, Durham, NC Arts District 2 (Level 2) MP406 LUNG TRANSPLANTATION FOR IPF N. Patel, MD, Penn Valley, PA Arts District 3 (Level 2) MP407 DIAGNOSIS AND TREATMENT OF RAPIDLY PROGRESSIVE INTERSTITIAL LUNG DISEASE S.M. Bhorade, MD, Chicago, IL Arts District 4 (Level 2) MP408 CANNABIS 2019: PROMISES AND PERILS OF THE GREEN CROSS E.L. Burnham, MD, Denver, CO Arts District 5 (Level 2) MP409 FROM PAP TO APP: NUTS AND BOLTS OF PEDIATRIC CPAP S. Bhargava, MD, Palo Alto, CA Arts District 6 (Level 2) MP410 ENDEMIC MYCOSES OF NORTH AMERICA AND BEYOND C.A. Hage, MD, ATSF, Indianapolis, IN Arts District 7 (Level 2) MP411 IDENTIFYING MIMICS OF IDIOPATHIC PULMONARY FIBROSIS: HOW AND WHY S. Dua, MD, New York, NY Cedars (Level 2) MP412 ADVANCED SLEEP LAB TITRATION PROTOCOLS FOR CHRONIC HYPOVENTILATION SYNDROMES W. Lee, MD, Dallas, TX South Side 1 (Level 3) ATS 2019 • Dallas, TX SUNDAY • MAY 19 97 SUNDAY MID-DAY